G R O U P   S T A T S

  • 27 members
  • 22 members have doctorate or medical degrees
  • Members' backgrounds include: Biochemistry, Bioengineering, Molecular and Cellular Biology, Epidemiology, Genetics, Immunology, Medical Biophysics, Neuroscience, Oncology, Psychobiology, and Toxicology

When it comes to advanced scientific degrees, we field the largest biotechnology group in New England — 28 members, over 80% of whom have PhDs or MDs. We aggressively recruit people who develop advanced technology, and who speak the language of inventors and scientists, quickly grasping complex biotechnology matters.

Client testimonial:
"They can come through on any technology; I’ve tested them on that. I have a good set of experience with other firms, and Wolf Greenfield has the depth and breadth."

Our clients include both large and emerging biotech companies such as Biogen, Dyax Corporation, and Lantheus Medical Imaging, privately financed startup companies, and prestigious academic and research institutions, including MIT, Dana Farber Cancer Institute, and Harvard Medical School. We understand the different needs of each client and bring practical solutions to the table.

Client testimonial:
"I don’t know that I’ve seen any other law firms produce anything better. Top quality, and they are able to act as business strategists as well."

Our expertise is broad and deep, covering areas from antibodies to transgenic technologies—and everything in between. We also call on members of our other practice groups including Chemical & Materials Technologies and Pharmaceutical when their specialized expertise will benefit a client’s project. In addition, our teams routinely include support from our paralegal group and our International Filing Department to contain costs and deliver value.

Client testimonial:
"The reputation is that they can handle complex matters very efficiently. In my experience, that is true. When there were some difficult or technical cases, I have gone to Wolf Greenfield."

Our group's services include: IP strategic planning; patent portfolio development, acquisition, and enforcement; studies on patentability, infringement, and validity; IP audits and due diligence; licensing and technology transfer; defending and challenging patent validity, including post-grant proceedings; and freedom to operate and competitor analyses.

Client testimonial:
"Wolf Greenfield has the ability to create IP opportunities for us that are worth millions."
  • We obtained dominating patents for an oncology company in a crowded area of antibody technology.
  • For a client with a contentious relationship with its competitor owning blocking patents, we prosecuted several interferences—including successful appeal to the Federal Circuit—which resulted in destroying all the competitor’s patents while leaving our client’s intact.
  • We advised an early stage biotech company in building a patent portfolio which was eventually licensed by a multinational pharmaceutical company in a deal worth close to $900 million.
  • We prosecuted one of the most widely licensed biotechnology patent portfolios, with over 70 licensees.
  • We obtained a Patent Term Extension of over three years for a biologic, representing over $900 million in projected sales.
  • For a pharmaceutical client in a crowded technology area, we pursued and obtained allowed claims on its next pipeline drug, raising company share price.
  • We have built pharmaceutical and biotech portfolios on which billions of funding has been based.
  • For a biotechnology client with a case suspended for years at the USPTO, we developed a prosecution strategy to move the case out of suspension, avoiding an interference, and resulting in a dominant patent.
  • We assisted a leading academic medical institution in securing patent protection for its licensed diagnostic test expected to be used on millions of patients and which is the basis of a new therapeutic indication.
  • We obtained seminal patents in the fields of gene therapy, phage display, and transgenic production of proteins in animals. We also managed the filing, prosecution, and licensing of several fundamental technologies in area of gene activation and cell signaling. 
  • For many academic and research institutes, we have developed and negotiated numerous university license agreements and established written patent policies and procedures to provide systematic structure to technology development and protection.
  • We managed the patent portfolio of a company in phase II/III clinical trial for an anti-cancer small molecule therapeutic.
  • For a start-up biotechnology client with a self-written provisional application, we crafted a comprehensive application suitable for filing in all geographies, resulting in a stronger business plan and a successful presentations to investors and potential business partners.

Representative clients:

  • Ablynx nv - Belgian biopharmaceutical company developing proprietary therapeutic proteins based on single-domain antibody fragments
  • Aura Biosciences, Inc. - start-up pharmaceutical company focused on developing drugs using tumor-targeted Viral Nanoparticles
  • Biogen Inc. - biotechnology company developing therapies for serious neurological, autoimmune, and hematologic disorders
  • Boehringer Ingelheim Corporation - pharmaceutical company, headquartered in Germany, working on new medications for human and veterinary medicine
  • Boston Children's Hospital - comprehensive center for pediatric health care
  • BTG plc - health care company developing products targeting acute care, cancer, and vascular diseases 
  • Dana-Farber Cancer Institute - cancer treatment hospital and research center
  • Dyax Corp. - biopharmaceutical company focused on developing and commercializing treatments for hereditary angioedema and identifying other disorders mediated by plasma kallikrein
  • Harvard University and Medical School - Harvard's Office of Technology Development is responsible for managing its intellectual property assets for the public good
  • ImmusanT, Inc. - biotechnology company developing treatments designed to replace gluten-free diet for celiac disease sufferers
  • The Jackson Laboratory - independent, nonprofit organization focusing on mammalian genetics research to advance human health
  • LFB Biotechnologies SAS - French pharmaceutical company specializing in biological medicinal products for patients with serious, often rare diseases
  • Ludwig Institute for Cancer Research - international nonprofit organization that conducts its own research and clinical trials
  • Massachusetts Institute of Technology - education and research institute managing commercial investment in and licensing of inventions and discoveries from research at MIT and Lincoln Laboratory
  • Ocata Therapeutics, Inc. - clinical-stage biotechnology company focused on new therapies in regenerative medicine
  • OrbiMed Advisors LLC - health care venture capital firm 
  • PathoGenetix, Inc. - biotechnology company developing automated system for rapid bacterial strain typing 
  • Pluristem Therapeutics, Inc. - clinical-stage biotechnology company using placental cells to develop cell therapies for broad spectrum of diseases
  • RaNA Therapeutics, Inc. - biotechnology company researching and developing new class of RNA-targeted medicines that selectively activate protein expression within a body’s own cells
  • rEVO Biologics, Inc. - biopharmaceutical company focused on development of therapeutics for rare diseases 
  • RXi Pharmaceuticals Corporation - biotechnology company focused on therapeutics primarily in areas of dermatology and ophthalmology
  • Selecta Biosciences, Inc. - clinical-stage biotechnology company developing novel drugs that use immune-modulating nanomedicines to generate antigen-specific immune responses to prevent and treat disease
  • Shire Pharmaceuticals - biopharmaceutical company focused on developing and marketing specialty medicines to meet significant unmet patient needs
  • Solid Ventures - venture capital company investing in promising drugs for Duchenne Muscular Dystrophy disease
  • University of Florida Research Foundation, Inc. -  UFRF promotes, encourages, and provides assistance to research activities of faculty, staff, and students
  • University of Massachusetts - UMass's Office of Technology Commercialization and Ventures commercializes the university's research results for the benefit of both the university and society
  • Yale University - Yale's Office of Cooperative Research facilitates the translation of research from Yale’s labs into products and services that benefit society

Recent Articles:

April 8, 2015
"Diagnostic patenting since Myriad: an update" by Patrick R. H. Waller and Daniel W. Young
Stakeholders shouldn’t conclude that nothing is patent eligible in the diagnostic space. Read more

March 2014
"
CRISPR/Cas-9: An Exciting Addition to Genomic Editing"
by Patricia Granahan and Chelsea A. Loughran
This article provides an in-depth review of (1) the science behind this new technology, (2) several of the research groups responsible for the promising applications for this technology, and (3) the related and evolving intellectual property (IP) landscape. Read more

February 2014
"
The New World of Diagnostic Testing Post-Myriad"
by Patrick R. H. Waller and Daniel W. Young
Claims to isolated DNA segments that exist in nature are not patent eligible, but claims to certain synthetic molecules relevant to genetic testing—as well as certain method-of-use patents—likely remain patent eligible. Read more

To view older publications, go to Publications


G R O U P   S T A T S

  • 27 members
  • 22 members have doctorate or medical degrees
  • Members' backgrounds include: Biochemistry, Bioengineering, Molecular and Cellular Biology, Epidemiology, Genetics, Immunology, Medical Biophysics, Neuroscience, Oncology, Psychobiology, and Toxicology

When it comes to advanced scientific degrees, we field the largest biotechnology group in New England — 28 members, over 80% of whom have PhDs or MDs. We aggressively recruit people who develop advanced technology, and who speak the language of inventors and scientists, quickly grasping complex biotechnology matters.

Client testimonial:
"They can come through on any technology; I’ve tested them on that. I have a good set of experience with other firms, and Wolf Greenfield has the depth and breadth."

Our clients include both large and emerging biotech companies such as Biogen, Dyax Corporation, and Lantheus Medical Imaging, privately financed startup companies, and prestigious academic and research institutions, including MIT, Dana Farber Cancer Institute, and Harvard Medical School. We understand the different needs of each client and bring practical solutions to the table.

Client testimonial:
"I don’t know that I’ve seen any other law firms produce anything better. Top quality, and they are able to act as business strategists as well."

Our expertise is broad and deep, covering areas from antibodies to transgenic technologies—and everything in between. We also call on members of our other practice groups including Chemical & Materials Technologies and Pharmaceutical when their specialized expertise will benefit a client’s project. In addition, our teams routinely include support from our paralegal group and our International Filing Department to contain costs and deliver value.

Client testimonial:
"The reputation is that they can handle complex matters very efficiently. In my experience, that is true. When there were some difficult or technical cases, I have gone to Wolf Greenfield."

Our group's services include: IP strategic planning; patent portfolio development, acquisition, and enforcement; studies on patentability, infringement, and validity; IP audits and due diligence; licensing and technology transfer; defending and challenging patent validity, including post-grant proceedings; and freedom to operate and competitor analyses.

Client testimonial:
"Wolf Greenfield has the ability to create IP opportunities for us that are worth millions."
  • We obtained dominating patents for an oncology company in a crowded area of antibody technology.
  • For a client with a contentious relationship with its competitor owning blocking patents, we prosecuted several interferences—including successful appeal to the Federal Circuit—which resulted in destroying all the competitor’s patents while leaving our client’s intact.
  • We advised an early stage biotech company in building a patent portfolio which was eventually licensed by a multinational pharmaceutical company in a deal worth close to $900 million.
  • We prosecuted one of the most widely licensed biotechnology patent portfolios, with over 70 licensees.
  • We obtained a Patent Term Extension of over three years for a biologic, representing over $900 million in projected sales.
  • For a pharmaceutical client in a crowded technology area, we pursued and obtained allowed claims on its next pipeline drug, raising company share price.
  • We have built pharmaceutical and biotech portfolios on which billions of funding has been based.
  • For a biotechnology client with a case suspended for years at the USPTO, we developed a prosecution strategy to move the case out of suspension, avoiding an interference, and resulting in a dominant patent.
  • We assisted a leading academic medical institution in securing patent protection for its licensed diagnostic test expected to be used on millions of patients and which is the basis of a new therapeutic indication.
  • We obtained seminal patents in the fields of gene therapy, phage display, and transgenic production of proteins in animals. We also managed the filing, prosecution, and licensing of several fundamental technologies in area of gene activation and cell signaling. 
  • For many academic and research institutes, we have developed and negotiated numerous university license agreements and established written patent policies and procedures to provide systematic structure to technology development and protection.
  • We managed the patent portfolio of a company in phase II/III clinical trial for an anti-cancer small molecule therapeutic.
  • For a start-up biotechnology client with a self-written provisional application, we crafted a comprehensive application suitable for filing in all geographies, resulting in a stronger business plan and a successful presentations to investors and potential business partners.

Representative clients:

  • Ablynx nv - Belgian biopharmaceutical company developing proprietary therapeutic proteins based on single-domain antibody fragments
  • Aura Biosciences, Inc. - start-up pharmaceutical company focused on developing drugs using tumor-targeted Viral Nanoparticles
  • Biogen Inc. - biotechnology company developing therapies for serious neurological, autoimmune, and hematologic disorders
  • Boehringer Ingelheim Corporation - pharmaceutical company, headquartered in Germany, working on new medications for human and veterinary medicine
  • Boston Children's Hospital - comprehensive center for pediatric health care
  • BTG plc - health care company developing products targeting acute care, cancer, and vascular diseases 
  • Dana-Farber Cancer Institute - cancer treatment hospital and research center
  • Dyax Corp. - biopharmaceutical company focused on developing and commercializing treatments for hereditary angioedema and identifying other disorders mediated by plasma kallikrein
  • Harvard University and Medical School - Harvard's Office of Technology Development is responsible for managing its intellectual property assets for the public good
  • ImmusanT, Inc. - biotechnology company developing treatments designed to replace gluten-free diet for celiac disease sufferers
  • The Jackson Laboratory - independent, nonprofit organization focusing on mammalian genetics research to advance human health
  • LFB Biotechnologies SAS - French pharmaceutical company specializing in biological medicinal products for patients with serious, often rare diseases
  • Ludwig Institute for Cancer Research - international nonprofit organization that conducts its own research and clinical trials
  • Massachusetts Institute of Technology - education and research institute managing commercial investment in and licensing of inventions and discoveries from research at MIT and Lincoln Laboratory
  • Ocata Therapeutics, Inc. - clinical-stage biotechnology company focused on new therapies in regenerative medicine
  • OrbiMed Advisors LLC - health care venture capital firm 
  • PathoGenetix, Inc. - biotechnology company developing automated system for rapid bacterial strain typing 
  • Pluristem Therapeutics, Inc. - clinical-stage biotechnology company using placental cells to develop cell therapies for broad spectrum of diseases
  • RaNA Therapeutics, Inc. - biotechnology company researching and developing new class of RNA-targeted medicines that selectively activate protein expression within a body’s own cells
  • rEVO Biologics, Inc. - biopharmaceutical company focused on development of therapeutics for rare diseases 
  • RXi Pharmaceuticals Corporation - biotechnology company focused on therapeutics primarily in areas of dermatology and ophthalmology
  • Selecta Biosciences, Inc. - clinical-stage biotechnology company developing novel drugs that use immune-modulating nanomedicines to generate antigen-specific immune responses to prevent and treat disease
  • Shire Pharmaceuticals - biopharmaceutical company focused on developing and marketing specialty medicines to meet significant unmet patient needs
  • Solid Ventures - venture capital company investing in promising drugs for Duchenne Muscular Dystrophy disease
  • University of Florida Research Foundation, Inc. -  UFRF promotes, encourages, and provides assistance to research activities of faculty, staff, and students
  • University of Massachusetts - UMass's Office of Technology Commercialization and Ventures commercializes the university's research results for the benefit of both the university and society
  • Yale University - Yale's Office of Cooperative Research facilitates the translation of research from Yale’s labs into products and services that benefit society

Recent Articles:

April 8, 2015
"Diagnostic patenting since Myriad: an update" by Patrick R. H. Waller and Daniel W. Young
Stakeholders shouldn’t conclude that nothing is patent eligible in the diagnostic space. Read more

March 2014
"
CRISPR/Cas-9: An Exciting Addition to Genomic Editing"
by Patricia Granahan and Chelsea A. Loughran
This article provides an in-depth review of (1) the science behind this new technology, (2) several of the research groups responsible for the promising applications for this technology, and (3) the related and evolving intellectual property (IP) landscape. Read more

February 2014
"
The New World of Diagnostic Testing Post-Myriad"
by Patrick R. H. Waller and Daniel W. Young
Claims to isolated DNA segments that exist in nature are not patent eligible, but claims to certain synthetic molecules relevant to genetic testing—as well as certain method-of-use patents—likely remain patent eligible. Read more

To view older publications, go to Publications